Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.

The diversity among cyclic nucleotide phosphodiesterases provides multiple mechanisms for regulation of cAMP and cGMP in the cardiovascular system. Here we report that a calmodulin-stimulated phosphodiesterase (PDE1C) is highly expressed in proliferating human arterial smooth muscle cells (SMCs) in primary culture, but not in the quiescent SMCs of intact human aorta. High levels of PDE1C were found in primary cultures of SMCs derived from explants of human newborn and adult aortas, and in SMCs cultured from severe atherosclerotic lesions. PDE1C was the major cAMP hydrolytic activity in these SMCs. PDE expression patterns in primary SMC cultures from monkey and rat aortas were different from those from human cells. In monkey, high expression of PDE1B was found, whereas PDE1C was not detected. In rat SMCs, PDE1A was the only detectable calmodulin-stimulated PDE. These findings suggest that many of the commonly used animal species may not provide good models for studying the roles of PDEs in proliferation of human SMCs. More importantly, the observation that PDE1C is induced only in proliferating SMCs suggests that it may be both an indicator of proliferation and a possible target for treatment of atherosclerosis or restenosis after angioplasty, conditions in which proliferation of arterial SMCs is negatively modulated by cyclic nucleotides.

[1]  J. Beavo,et al.  Multiplicity within cyclic nucleotide phosphodiesterases. , 1996, Biochemical Society transactions.

[2]  J. Beavo,et al.  The Calmodulin-dependent Phosphodiesterase Gene PDE1C Encodes Several Functionally Different Splice Variants in a Tissue-specific Manner* , 1996, The Journal of Biological Chemistry.

[3]  K. Bornfeldt Intracellular Signaling in Arterial Smooth Muscle Migration versus Proliferation. , 1996, Trends in cardiovascular medicine.

[4]  Ravi Iyengar Gating by Cyclic AMP: Expanded Role for an Old Signaling Pathway , 1996, Science.

[5]  K. Sadhu,et al.  Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3′,5′-Cyclic Nucleotide Phosphodiesterases (*) , 1996, The Journal of Biological Chemistry.

[6]  M. Pfaffendorf,et al.  Effect of phosphodiesterase inhibitors on human arteries in vitro. , 1996, British journal of anaesthesia.

[7]  W. K. Sonnenburg,et al.  Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases (*) , 1995, The Journal of Biological Chemistry.

[8]  K. Ferguson,et al.  Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[10]  T. Shiraishi,et al.  Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021. , 1995, European journal of pharmacology.

[11]  E. Krebs,et al.  cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Beavo,et al.  Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. , 1995, Molecular pharmacology.

[13]  J. Vane,et al.  Pharmacodynamic profile of prostacyclin. , 1995, The American journal of cardiology.

[14]  J. Blenis,et al.  Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP , 1995, Molecular and cellular biology.

[15]  J. Massagué,et al.  Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 Kip1 ) of cyclin-dependent kinase 4 activation , 1994, Cell.

[16]  R. A. Murphy,et al.  Cyclic nucleotide dependent relaxation in vascular smooth muscle. , 1994, Canadian journal of physiology and pharmacology.

[17]  C. Lugnier,et al.  Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway , 1994, British journal of pharmacology.

[18]  J. Polson,et al.  Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. , 1994, Biochemical pharmacology.

[19]  S. Davies,et al.  Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. , 1994, British heart journal.

[20]  S. Cook,et al.  Inhibition by cAMP of Ras-dependent activation of Raf. , 1993, Science.

[21]  P. Dent,et al.  Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. , 1993, Science.

[22]  E. Krebs,et al.  Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Saeki,et al.  Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. , 1993, Biochemical pharmacology.

[24]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[25]  W. K. Sonnenburg,et al.  Molecular cloning of a cDNA encoding the "61-kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. , 1993, The Journal of biological chemistry.

[26]  M. Hallett,et al.  Inhibition of proliferation, but not of Ca2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. , 1992, The Biochemical journal.

[27]  W. K. Sonnenburg,et al.  Molecular cloning of cDNA encoding a "63"-kDa calmodulin-stimulated phosphodiesterase from bovine brain. , 1992, The Journal of biological chemistry.

[28]  G. Hassall,et al.  Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. , 1992, Biochemical pharmacology.

[29]  C. Heiner,et al.  Rapid and reliable fluorescent cycle sequencing of double-stranded templates. , 1992, DNA sequence : the journal of DNA sequencing and mapping.

[30]  E. Sybertz,et al.  Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. , 1992, Advances in second messenger and phosphoprotein research.

[31]  E. Degerman,et al.  Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. , 1991, Biochemical pharmacology.

[32]  J. Thyberg,et al.  Regulation of differentiated properties and proliferation of arterial smooth muscle cells. , 1990, Arteriosclerosis.

[33]  R. Hurwitz,et al.  Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis. , 1990, The Journal of biological chemistry.

[34]  V. Flintoft,et al.  Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. , 1990, Journal of the American College of Cardiology.

[35]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[36]  K. Struhl,et al.  Current Protocols in Molecular Biology (New York: Greene Publishing Associates and Wiley-Interscience). Host-Range Shuttle System for Gene Insertion into the Chromosomes of Gram-negative Bacteria. , 1988 .

[37]  R. Hansen,et al.  Purification of calmodulin-stimulated cyclic nucleotide phosphodiesterase by monoclonal antibody affinity chromatography. , 1988, Methods in enzymology.

[38]  M. Cohen,et al.  In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. , 1987, The Journal of pharmacology and experimental therapeutics.

[39]  C. Lugnier,et al.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. , 1986, Biochemical pharmacology.

[40]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.